Dapsone

Generic Name: Dapsone

Brand Names: Aczone

Drug Type: Small Molecule

Chemical Formula: C_₁₂H_₁₂N_₂O_₂S

CAS Number: 80-08-0

Unique Ingredient Identifier: 8W5C518302

Background: A sulfone active against a wide range of bacteria but mainly employed for its actions against mycobacterium leprae. Its mechanism of action is probably similar to that of the sulfonamides which involves inhibition of folic acid synthesis in susceptible organisms. It is also used with pyrimethamine in the treatment of malaria. (From Martindale, The Extra Phar...

Indication: For the treatment and management of leprosy and dermatitis herpetiformis.

Associated Conditions: Acne Vulgaris, Bullous Systemic Lupus Erythematosus, Bullous dermatitis herpetiformis, Hansen's Disease, Pemphigus Vulgaris (PV), Relapsing Polychondritis, Mild Pneumocystis pneumonia, Mild Toxoplasma gondii encephalitis, Moderate Pneumocystis pneumonia, Moderate Toxoplasma gondii encephalitis, Refractory Idiopathic thrombocytopenic purpura

Associated Therapies: -

Clinical Trials

Efficacy and Safety of add-on Dapsone Versus add-on Methotrexate in Patients With Bullous Pemphigoid

Phase 4

Recruiting

Conditions: Bullous Pemphigoid

Interventions: Drug: Prednisolone
Drug: Dapsone
Drug: Methotrexate

First Posted Date: 2023-08-09

Last Posted Date: 2023-12-13

Lead Sponsor: All India Institute of Medical Sciences, Bhubaneswar

Target Recruit Count: 62

Registration Number: NCT05984381

Locations: 🇮🇳
AIIMS Bhubaneswar, Bhubaneswar, Odisha, India

Dapsone Use in Patients With Aneurysmal Subarachnoid Hemorrhage.

Phase 3

Completed

Conditions: Subarachnoid Hemorrhage
Brain Ischemia
Subarachnoid Hemorrhage, Aneurysmal
Aneurysmal Subarachnoid Hemorrhage
Delayed Cerebral Ischemia
Vasospasm, Cerebral

Interventions: Drug: Dapsone
Drug: Aluminum Hydroxide Gel

First Posted Date: 2021-11-23

Last Posted Date: 2021-11-23

Lead Sponsor: El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez

Target Recruit Count: 49

Registration Number: NCT05131295

Locations: 🇲🇽
El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez, Mexico City, Mexico

Study Comparing Test to Aczone 7.5% and Both to a Placebo Control in the Treatment of Acne Vulgaris

Phase 1

Completed

Conditions: Acne Vulgaris

Interventions: Drug: Placebo
Drug: Aczone
Drug: DPSG 7.5%

First Posted Date: 2017-04-27

Last Posted Date: 2017-05-04

Lead Sponsor: Taro Pharmaceuticals USA

Target Recruit Count: 1125

Registration Number: NCT03132194

A Randomized Multicenter Study for Isolated Skin Vasculitis

Phase 2

Recruiting

Conditions: Primary Cutaneous Vasculitis
Cutaneous Polyarteritis Nodosa
IgA Vasculitis
Henoch-Schönlein Purpura

Interventions: Drug: Colchicine
Drug: Dapsone
Drug: Azathioprine

First Posted Date: 2016-10-20

Last Posted Date: 2024-02-01

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 90

Registration Number: NCT02939573

Locations: 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸
Boston University School of Medicine, Boston, Massachusetts, United States
🇺🇸
Penn State Hershey Medical Center, Hershey, Pennsylvania, United States

and more 13 locations

Clinical Utility Of Genetic Screening For HLA-B*1301, On Susceptibility To Dapsone Hypersensitivity Syndrome

Phase 4

Conditions: Allergic Cutaneous Vasculitis
Urticaria
Psoriasis
Sterile Pustulosis
Leprosy
Acne
Pneumocystis Pneumonia
Bullous Skin Diseases

Interventions: Drug: Dapsone
Genetic: HLA-B*1301

First Posted Date: 2015-09-15

Last Posted Date: 2017-03-03

Lead Sponsor: Shandong Provincial Institute of Dermatology and Venereology

Target Recruit Count: 3130

Registration Number: NCT02550080

Locations: 🇨🇳
Shandong Provincial Institute of Dermatology and Venereology, Jinan, Shandong, China

Effect of Weight and/or Obesity on Dapsone Drug Concentrations

Phase 4

Completed

Conditions: Obesity
Tuberculosis
Leprosy

Interventions: Drug: Dapsone

First Posted Date: 2010-07-20

Last Posted Date: 2016-07-21

Lead Sponsor: Texas Tech University Health Sciences Center

Target Recruit Count: 37

Registration Number: NCT01165840

Locations: 🇺🇸
University of Texas Southwestern, Dallas, Texas, United States

Dapsone for Acute Ischemia Stroke Study

Phase 2

Conditions: Cerebral Stroke
Cerebrovascular Accident, Acute
Cerebrovascular Stroke
Stroke, Acute
Stroke

Interventions: Drug: Placebo
Drug: Dapsone

First Posted Date: 2010-06-15

Last Posted Date: 2010-06-15

Lead Sponsor: Cidat, S.A. de C.V.

Target Recruit Count: 300

Registration Number: NCT01144650

Locations: 🇲🇽
El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez, Tlalpan, Mexico City., Mexico

Methemoglobinemia in Young Patients With Hematologic Cancer or Aplastic Anemia Treated With Dapsone

Completed

Conditions: Nonmalignant Neoplasm
Myelodysplastic Syndromes
Lymphoma
Chronic Myeloproliferative Disorders
Lymphoproliferative Disorder
Leukemia
Methemoglobinemia
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic/Myeloproliferative Neoplasms

First Posted Date: 2009-10-12

Last Posted Date: 2017-04-17

Lead Sponsor: Vanderbilt University

Target Recruit Count: 41

Registration Number: NCT00993694

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center - Cool Springs, Nashville, Tennessee, United States
🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

Dapsone Gel 5% and Tazarotene Cream 0.1% Versus Tazarotene Cream 0.1% Monotherapy for Facial Acne Vulgaris

Phase 4

Completed

Conditions: Acne Vulgaris

Interventions: Drug: Dapsone
Drug: Tazarotene

First Posted Date: 2009-02-03

Last Posted Date: 2011-10-31

Lead Sponsor: Allergan

Target Recruit Count: 171

Registration Number: NCT00834210

Efficacy of Dapsone as a Steroid Sparing Agent in Pemphigus Vulgaris

Phase 2

Terminated

Conditions: Pemphigus Vulgaris

First Posted Date: 2007-01-31

Last Posted Date: 2007-02-05

Lead Sponsor: Jacobus Pharmaceutical

Target Recruit Count: 48

Registration Number: NCT00429533

Locations: 🇺🇸
Henry Ford Hospital, Detroit, Michigan, United States
🇺🇸
Cooper Hospital/University Medical Center, Camden, New Jersey, United States
🇺🇸
Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois, United States

and more 5 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy